BARCELONA, Spain and NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection, today announced that it will present preclinical data on its unique series of HBV Core Protein Allosteric Modifiers (CpAMs) at the upcoming International Liver CongressTM 2016 in Barcelona, Spain.
The presentation, titled Abstract FRI-104: Preclinical Characterization of Potent Core Protein Allosteric Modifiers for the Treatment of Chronic Hepatitis B, will be presented on Friday, April 15, 2016 during a Hepatitis Poster Session starting at 8:00 am local time. Click here to locate and view the presentation Abstract, which is also posted on the Investor page of the company’s website.
Assembly’s Core Protein Allosteric Modifiers are a novel class of direct acting antivirals for the treatment of chronic HBV. Assembly’s EASL presentation characterizes a novel series of potent, pan-genotypic CpAMs that are designed to be used alone or in combination with current standard of care HBV therapies to achieve higher rates of cure. Representative molecules in the series demonstrated potent HBV antiviral activity, a positive in vitro safety profile and promising pharmacokinetic properties. The authors conclude that the potency, favorable preclinical activity and positive preclinical safety profiles demonstrated by these molecules support selection of a CpAM from the series to advance into Phase 1 clinical studies.
About Assembly Biosciences
Assembly Biosciences, Inc. is a public biotechnology company advancing both a new class of oral biologic therapeutics for addressing the gut microbiome and novel approaches to discovering and developing drugs for the treatment of hepatitis B virus (HBV) infection. Assembly’s team has significant experience in infectious disease drug discovery and development and has collectively helped bring more than 10 anti-infective products to the market. The company’s HBV-Cure Program is aimed at increasing the current low cure rate for patients with chronic HBV. It is pursuing a number of drug candidates that inhibit multiple viral targets throughout the HBV lifecycle for possible use alone or in combination therapy. The company’s Microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under cGMP conditions, and a patent pending delivery system, GEMICELTM, which allows for targeted oral delivery of live biologic and conventional therapies to the lower GI tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile infection. For more information, visit assemblybio.com.
Cautionary Statement Regarding Forward-Looking Statements
The information provided herein contains estimates and other forward-looking statements regarding future events, including statements about the therapeutic potential of our HBV-Cure and Microbiome programs and the potential initiation of Phase 1 clinical studies of a CpAM. Such statements, which we intend to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: preclinical models may not be representative of disease behavior in clinical studies; our ability to retain necessary employees and to staff our operations appropriately; the components, timing, cost and results of clinical trials and other development activities involving our product candidates; the unpredictability of the preclinical and clinical development of our product candidates and of the duration and results of regulatory review of those candidates by the FDA and foreign regulatory authorities and the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed with the Securities and Exchange Commission. It is not possible for Assembly management to predict all risks nor can Assembly assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Assembly may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Assembly Biosciences, Inc.
BLL Partners LLC